The Epithelial Cell Transforming Sequence 2 (ECT2) Antibody, Biotin Conjugated is a specialized immunological reagent designed to detect and study the ECT2 protein, a guanine nucleotide exchange factor (GEF) critical in regulating Rho GTPases and cellular processes such as cytokinesis and ribosomal biogenesis . Biotin conjugation enhances the antibody’s utility in assays requiring signal amplification, leveraging the high-affinity interaction between biotin and streptavidin/avidin systems .
ECT2 antibodies target specific amino acid regions of the protein:
Polyclonal Rabbit Origin: Ensures broad epitope recognition .
Biotin Conjugation: Enables detection via streptavidin-HRP, streptavidin-Alexa Fluor, or streptavidin-coated beads .
Phospho-Specific Variants: Detect phosphorylated ECT2 (e.g., pThr790), critical for studying mitotic regulation .
Biotin-conjugated ECT2 antibodies amplify signals in:
| Application | Recommended Dilution |
|---|---|
| WB | 1:500–1:3000 |
| IHC | 1:10–1:50 |
| IF/ICC | 1:200–1:800 |
| Flow Cytometry | 0.25 µg/10⁶ cells |
ECT2 regulates Rho GTPases (e.g., RhoA, Rac1, Cdc42) during cell division. Biotin-conjugated antibodies have elucidated:
Mitotic Localization: ECT2 spreads throughout the cytoplasm during prometaphase and condenses in the midbody during cytokinesis .
Phosphorylation-Dependent Activity: Phosphorylation at Thr790 enhances ECT2’s GEF activity, critical for mitotic progression .
In non-small-cell lung cancer (NSCLC), ECT2 binds the transcription factor UBF1 on ribosomal DNA (rDNA) promoters:
BRCT Domain Dependency: The ECT2 BRCT domain mediates interaction with phosphorylated UBF1 (Ser412) .
PKCι-Mediated Phosphorylation: Protein kinase Cι (PKCι) phosphorylates UBF1, enabling ECT2 recruitment and rRNA synthesis .
Cancer Targeting: Overexpression of ECT2 in tumors correlates with aggressive growth. Biotin-conjugated antibodies enable precise detection for diagnostic or therapeutic monitoring .
Universal CAR T Cells: Biotin-streptavidin systems enhance tumor targeting, as demonstrated in HER2+ breast and pancreatic cancers .